Read More Pharma Industry News Why NCEL-101’s FDA pathway could influence the future of stem-cell-derived islet therapies Why NewcelX Ltd.’s FDA pre-IND process for NCEL-101 could shape the future of regenerative diabetes medicine. Read the full analysis. bySoujanya RaviMay 30, 2026